These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32484706)

  • 1. Does the platelet‑to‑lymphocyte ratio have a prognostic effect in patients with myelodysplastic syndrome?
    Yikilmaz AS; Akinci S; Bakanay SM; Dilek I
    Bratisl Lek Listy; 2020; 121(6):422-427. PubMed ID: 32484706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the bone marrow histology between childhood myelodysplastic syndrome with multilineage dysplasia and refractory cytopenia of childhood without multilineage dysplasia.
    Iwafuchi H; Ito M
    Histopathology; 2019 Jan; 74(2):239-247. PubMed ID: 30062702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
    Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR
    Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts.
    Font P; Loscertales J; Soto C; Ricard P; Novas CM; Martín-Clavero E; López-Rubio M; Garcia-Alonso L; Callejas M; Bermejo A; Benavente C; Ballesteros M; Cedena T; Calbacho M; Urbina R; Villarrubia J; Gil S; Bellón JM; Diez-Martin JL; Villegas A
    Ann Hematol; 2015 Apr; 94(4):565-73. PubMed ID: 25387664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
    Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
    Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoplastic myelodysplastic syndrome.
    Nand S; Godwin JE
    Cancer; 1988 Sep; 62(5):958-64. PubMed ID: 3409176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
    Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
    J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification.
    Verburgh E; Achten R; Louw VJ; Brusselmans C; Delforge M; Boogaerts M; Hagemeijer A; Vandenberghe P; Verhoef G
    Leukemia; 2007 Apr; 21(4):668-77. PubMed ID: 17301818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
    Wang H; Wang XQ; Xu XP; Lin GW
    Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Myelodysplastic syndrome: a review].
    Creutzig U; Hoelzer D
    Klin Padiatr; 1987; 199(3):169-72. PubMed ID: 3626418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum Erythropoietin as Prognostic Marker in Myelodysplastic Syndromes].
    Cortesão E; Tenreiro R; Ramos S; Pereira M; César P; Carda JP; Gomes M; Rito L; Magalhães E; Gonçalves AC; Silva NC; Geraldes C; Pereira A; Ribeiro L; Nascimento Costa JM; Ribeiro AB
    Acta Med Port; 2015; 28(6):720-5. PubMed ID: 26849756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
    Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
    Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients.
    Maschek H; Gutzmer R; Choritz H; Georgii A
    Eur J Haematol; 1994 Nov; 53(5):280-7. PubMed ID: 7813708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes.
    Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
    Int J Hematol; 1993 Aug; 58(1-2):53-61. PubMed ID: 8219112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
    Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
    Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis.
    Sashida G; Takaku TI; Shoji N; Nishimaki J; Ito Y; Miyazawa K; Kimura Y; Ohyashiki JH; Ohyashiki K
    Leuk Lymphoma; 2003 Apr; 44(4):653-8. PubMed ID: 12769343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.